- Globe Newswire
Italy Wound Care Management Procedures Outlook to 2025 - Ostomy Procedures, Tissue Engineered - Skin Substitute Procedures and Wound Debridement Procedures
Summary “Italy Wound Care Management Procedures Outlook to 2025” is a comprehensive databook report, covering key procedures data on the Italy Wound Care Management Procedures.New York, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Italy Wound Care Management Procedures Outlook to 2025 - Ostomy Procedures, Tissue Engineered - Skin Substitute Procedures and Wound Debridement Procedures" - https://www.reportlinker.com/p05190838/?utm_source=GNW The databook report provides procedure volumes within segments - Ostomy, Tissue Engineered - Skin Substitute and Wound Debridement. The Italy Wound Care Management Procedures report provides key information and data on - \- Procedure volume data for Wound Care Management Procedures related to the country. Data is provided from 2015 to 2025. Scope Italy Wound Care Management Procedures is segmented as follows - \- Ostomy Procedures \- Tissue Engineered - Skin Substitute Procedures \- Wound Debridement Procedures Reasons to Buy The Italy Wound Care Management Procedures report helps you to develop - \- Business strategies by identifying the key segments poised for strong growth in the future. \- Market-entry and market expansion strategies. \- Develop investment strategies by identifying the key segments expected to register strong growth in the near future. Read the full report: https://www.reportlinker.com/p05190838/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
The Guardian'Peace where rights aren’t trampled': Afghan women's demands ahead of Taliban talks
'Peace where rights aren’t trampled': Afghan women's demands ahead of Taliban talksWith negotiations set to begin, women have been sharing their ‘red lines’ on the progress they refuse to see negotiated
- EQS Group
Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
Hardman & Co Research 13-Aug-2020 / 07:15 GMT/BST Hardman & Co Research: Flow of regulatory approvalsDiurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) is currently being rolled out throughout Europe, and recent approvals in Israel and Australia will open up more markets. Approaching next month, all attention will turn towards the US, where the PDUFA date has been set for 29 September. Upfront cash from the US commercial deal with Eton Pharmaceuticals (Eton), together with the recent Placing, has strengthened the balance sheet.https://www.hardmanandco.com/research/corporate-research/flow-of-regulatory-approvals/If you are interested in meeting the company, you can register your interest by clicking on the above link.To contact us:Hardman & Co 35 New Broad Street London EC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCoContact:Dr Martin Hall +44 20 7194 7622 mh@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
